Table 1.
Demographic and biomedical information on participants 3 months after treatment.
| Not at risk at 3 months (N = 50) | At risk at 3 months (N = 50) | Overall (N = 100) | |
|---|---|---|---|
| Gender (female) | 32% (16) | 28% (14) | 30% (30) |
| Age (years) | 48.7 (10.1) | 46.0 (11.3) | 47.3 (10.8) |
| BMI (kg/m2) | 25.0 (5.9) | 25.0 (4.4) | 25.0 (5.2) |
| Smoking | 74% (37) | 78% (39) | 76% (76) |
| Active | 54% (27) | 47% (23) | 51% (50*) |
| Married | 58% (29) | 47% (23) | 53% (52*) |
| Psychiatric disorder | 48% (24) | 70% (35) | 59% (59) |
| Psychotrope use | 54% (27) | 74% (37) | 64% (64) |
| Benzodiazepine | 48% (24) | 64% (32) | 56% (56) |
*1 missing observation.